

# Omega Funds co-leads Spruce Biosciences' \$88M Series B

Client News

February 19, 2020

Gunderson Dettmer client Omega Funds co-led the \$88 million Series B financing of Spruce Biosciences, a bio-pharmaceutical company developing novel therapies for rare endocrine diseases. Abingworth Management also co-led the financing.

In [the announcement of the transaction](#) Dina Chaya, Advisor to Omega Funds, said “We are impressed with the potential for tildacerfont to become the first approved treatment for patients with classic congenital adrenal hyperplasia around the world, as well as the encouraging positive results recently announced from its Phase 2 clinical trial. This drug could be a life-altering therapy for patients with CAH.”

The Gunderson Dettmer deal team was led by Jeffrey Engerman and included Kelvin Chan, Misola Ijidakinro and Andrew Weymouth.

## Related People



Jeffrey M. Engerman

PARTNER

P +1 617 648 9175



Kelvin W. Chan

ASSOCIATE

P +1 617 648 9333

## Related Services

Private Fund

Seed, Venture and Growth Financings

## Featured Insights

PUBLIC VENTURES

Trump Executive Order Targets Proxy Advisors Over DEI and ESG Influence

EVENTS

Webinar: Paradigm Shift? Mandatory Securities Arbitration and the Impact of the SEC's Recent Policy Statement for Companies and Investors

FIRM NEWS

Amidst Strong Year, Gunderson Dettmer Elects Nine New Partners

EVENTS

Webinar: AI in the Workplace: Legal Challenges and Best Practices

FIRM NEWS

2025 CVCA Annual General Meeting & Private/Venture Capital Summit in

Beijing

CLIENT NEWS

Gunderson Dettmer Represented Hims & Hers in Acquisition of Livewell

CLIENT NEWS

Replicate Bioscience Announces Collaborative Agreement with Instituto Butantan

CLIENT NEWS

Gunderson Client Neptune to Be Acquired by OpenAI

CLIENT NEWS

Hims & Hers Announces Definitive Agreement to Acquire YourBio Health

CLIENT NEWS

LotusFlare Announces Equity Investment from Ericsson

PUBLIC VENTURES

SEC Chair Charts Disclosure Overhaul to Revive IPOs: Materiality and Scale Over 'Regulatory Creep'

CLIENT NEWS

Vambe Raises \$14M Series A Led by Monashees